Ixazomib citrate

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ixazomib citrate

CAS No. : 1239908-20-3

MCE 国际站：Ixazomib citrate

产品活性：Ixazomib citrate (MLN9708) 是 20S蛋白酶体胰凝乳蛋白酶样蛋白水解β5位点的可逆抑制剂，IC₅₀ 为3.4 nM和K_i为0.93 nM。

研究领域：Metabolic Enzyme/Protease  |  Autophagy

作用靶点：Proteasome  |  Autophagy

In Vitro: Ixazomib citrate (MLN9708; 0.20-3.20 μM) inhibits the cell growth of both cell lines effectively in a time- and dose-dependent manner. Ixazomib induces cell cycle arrest in MG-63 and Saos-2 cells. Ixazomib induces apoptosis mainly through the caspases pathway and requires the activation of both caspase8 and caspase9. Ixazomib treatment increases the levels of pro-apoptotic proteins and down regulates the anti-apoptotic proteins that control MOMP. Ixazomib treatment induces the release of Cytc, Smac, OMI from mitochondria and decreases the protein levels of XIAP. Ixazomib inhibits the invasion ability of MG-63 and Saos-2 cells and decreases both the expression and secretion levels of MMP2/9.Ixazomib citrate (MLN9708; 12 nM) shows inhibitory activity against C-L and T-L proteasome activities. Treatment of H929 and MM.1S MM cells with Ixazomib triggers a marked increase in proteolytic cleavage of poly(ADP) ribose polymerase (PARP), a signature event during apoptosis. Ixazomib induces cleavage of caspase-3, an upstream activator of PARP. Ixazomib induces eIf2-α kinase activity and protein levels of Bip and CHOP/GADD153. Ixazomib blocks BMSCs-induced MM cell proliferation, inhibits in vitro capillary tubule formation, and target NF-κB.

In Vivo: Ixazomib citrate (MLN9708; 11 mg/kg) significantly inhibits MM tumor growth and prolongs survival in the human plasmacytoma MM.1S xenograft mouse model. The blood chemistry profiles of Ixazomib-treated mice show normal levels of creatinine, hemoglobin, and bilirubin. Ixazomib dramatically increases the number of cleaved-caspase-3 positive cells of the xenograft model.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  Ubiquitination Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Blood Cancer Compound Library  |  Targeted Therapy Drug Library   |  Rare Diseases Drug Library  |  FDA-Approved Anticancer Drug Library  |  Cell Death Library  |  MG-132  |  Bortezomib  |  Carfilzomib  |  Celastrol  |  Ixazomib  |  Epoxomicin  |  Isoginkgetin  |  Calpeptin  |  ONX-0914  |  PD150606  |  MG-101  |  Marizomib  |  Capzimin  |  MDL-28170  |  18α-Glycyrrhetinic acid  |  Oprozomib  |  K-7174 dihydrochloride  |  Aclacinomycin A hydrochloride  |  Delanzomib  |  PD 151746  |  Zetomipzomib maleate  |  Isovalerylcarnitine  |  KZR-504  |  M3258  |  TCH-165  |  RA190  |  Tomatine  |  Alicapistat

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds